Distinct immunologic effects of different intravenous iron preparations on monocytes

Nephrology Dialysis Transplantation

Volumn 29, Issue 4, 2014, Pages 809-822

  Fell, Lisa H ^a   Zawada, Adam M ^a   Rogacev, Kyrill S ^a   Seiler, Sarah ^a   Fliser, Danilo ^a   Heine, Gunnar H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

CD14; CD16; immune deficiency; iron therapy; monocyte subsets

Indexed keywords

CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; FERRIC CARBOXYMALTOSE; FERUMOXYTOL; INTERLEUKIN 1BETA; IRON DERIVATIVE; IRON DEXTRAN; IRON ISOMALTOSIDE 1000; IRON SACCHARATE; MONOFER; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANEMIA; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL DIFFERENTIATION; CELL PHAGOCYTOSIS; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IRON DEFICIENCY; MONOCYTE; PRIORITY JOURNAL;

CD14; CD16; IMMUNE DEFICIENCY; IRON THERAPY; MONOCYTE SUBSETS;

ANEMIA, IRON-DEFICIENCY; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINES; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; MONOCYTES; OXIDATIVE STRESS; PHAGOCYTOSIS;

EID: 84897423286     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft524     Document Type: Article

References (41)

1. Group KDIGOKAW. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335
2. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
3. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
4. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
5. Joshi AD, Holdford DA, Brophy DF et al. Utilization patterns of IV iron and erythropoiesis stimulating agents in anemic chronic kidney disease patients: A multihospital study. Anemia 2012; 2012: 248430
6. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080
7. Theurl I, Theurl M, Seifert M et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008; 111: 2392-2399
8. Alleyne M, Horne MK, Miller JL. Individualized treatment for irondeficiency anemia in adults. Am J Med 2008; 121: 943-948
9. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984
10. Jahn MR, Andreasen HB, Futterer S et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78: 480-491
11. Li H, Wang SX. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int 2008; 28: 149-154
12. Kooistra MP, Kersting S, Gosriwatana I et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32(Suppl 1): 36-41
13. Brissot P, Ropert M, Le Lan C et al. Non-Transferrin bound iron: A key role in iron overload and iron toxicity. Biochim Biophys Acta 2012; 1820: 403-410
14. Pai AB, Conner T, McQuade CR et al. Non-Transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011; 24: 603-613
15. Collard K, White D, Copplestone A. The effect of maximum storage on iron status, oxidative stress and antioxidant protection in paediatric packed cell units. Blood Transfus 2013; 11: 419-425
16. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-99
17. Ichii H, Masuda Y, Hassanzadeh T et al. Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol 2012; 36: 50-57
18. Patruta SI, Edlinger R, Sunder-Plassmann G et al. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9: 655-663
19. Sonnweber T, Theurl I, Seifert M et al. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant 2011; 26: 977-987
20. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009; 1790: 682-693
21. Ziegler-Heitbrock L, Ancuta P, Crowe S et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: E74-e80
22. Zawada AM, Rogacev KS, Rotter B et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118: E50-e61
23. Rogacev KS, Seiler S, Zawada AM et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32: 84-92
24. Bailie GR, Larkina M, Goodkin DA et al. Variation in intravenous iron use internationally and over time: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28: 2570-2579
25. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
26. Harnett JD, Foley RN, Kent GM et al. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-890
27. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
28. Zager RA, Johnson AC, Hanson SY et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103
29. Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease: An update. Iran J Kidney Dis 2013; 7: 9-22
30. Belge KU, Dayyani F, Horelt A et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-3542
31. Martin-Malo A, Merino A, Carracedo J et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012; 27: 2465-2471
32. Zawada AM, Rogacev KS, Schirmer SH et al. Monocyte heterogeneity in human cardiovascular disease. Immunobiology 2012; 217: 1273-1284
33. Deicher R, Ziai F, Cohen G et al. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728-736
34. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12-33
35. Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des Devel Ther 2012; 6: 43-51
36. Futterer S, Andrusenko I, Kolb U et al. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and Xray powder diffraction (XRPD). J Pharm Biomed Anal 2013; 86: 151-160
37. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15(Suppl 2): S93-S98
38. Cabantchik ZI, Breuer W, Zanninelli G et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277-287
39. Pootrakul P, Breuer W, Sametband M et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded betathalassemia/HbE patients treated with an oral chelator. Blood 2004; 104: 1504-1510
40. Evans RW, Rafique R, Zarea A et al. Nature of non-Transferrin-bound iron: Studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem 2008; 13: 57-74
41. Chrichton RR, Danielson BG, Geisser P. Iron Therapy with Special Emphasis on Intravenous Administration. Bremen, Germany: UNI-MED Science, 2008